Drugs News and Research

RSS

Johns Hopkins to test all children for 'superbugs'

Infection control and critical care experts at The Johns Hopkins Hospital have ordered testing for the two most common hospital superbugs for every child admitted to its pediatric intensive care unit.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

AHIP develops new initiatives to improve the quality and safety of health care

The proposal includes reforms to the FDA and a plan for comparing the effectiveness of prescription drugs, devices and new medical technologies.

17 Apr 2007

AARP to track Senate vote on Medicare Rx bargaining bill

Today, AARP will be sending the following letter from CEO Bill Novelli to every member of the U.S. Senate alerting them that the association will be recording the upcoming Senate vote on a bill to allow Medicare to negotiate for lower prescription drug prices.

17 Apr 2007

Too many of the world's poor still denied HIV drugs

According to a new report by the World Health Organization (WHO), UNAIDS and UNICEF, only 28% of the world's poor with HIV have access to the antiretroviral drugs that could save their lives.

17 Apr 2007

New chemical agent, MCP110, provides synergistic effect to standard drugs

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.

16 Apr 2007

Chaetocin shows promise as a new anti-myeloma agent

Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.

16 Apr 2007

Eating well still one of the best ways to prevent cancer and promote good health

We all know that eating fruits, vegetables and soy products provides essential nutrition for a healthy lifestyle, while obesity leads to the opposite.

16 Apr 2007

Leukemic cells find safe haven in bone marrow

The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to St. Jude investigators.

16 Apr 2007

High blood pressure could be a brain problem

Scientists in Britain say the cause of high blood pressure may lie within the brain, rather than with problems relating to the heart, kidneys or blood vessels.

16 Apr 2007

Potential of nanotechnology in medicine

Scientists are working now to create novel nanostructures that serve as new kinds of drugs for treating cancer, Parkinson's and cardiovascular disease; to engineer nanomaterials for use as artificial tissues that would replace diseased kidneys and livers, and even repair nerve damage; and to integrate nanodevices with the nervous system to create implants that restore vision and hearing, and build new prosthetic limbs.

15 Apr 2007

Should stocks of smallpox virus be destroyed?

Smallpox was eradicated in 1980, but the virus still exists in WHO controlled depositories. In this week's BMJ , two experts go head to head over whether these stocks should be destroyed.

15 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

Use of computer-assisted drug design in drug discovery

Metabasis Therapeutics has announced that on March 27, 2007 at the American Chemical Society 233rd National Meeting and Exposition in Chicago, Dr. M. Rami Reddy presented, "Use of Computer-Assisted Drug Design in Drug Discovery: Limitations and Advantages of Available Computational Methods."

15 Apr 2007

Lupin Pharmaceuticals receives FDA approval for Suprax

Lupin Pharmaceuticals has announced that the U.S. Food and Drug Administration (US FDA) has approved the company's application for Suprax (Cefixime for oral suspension 200mg/5ml).

15 Apr 2007

New perspectives on risk taking in adolescence

While the government spends billions of dollars on educational and prevention programs to persuade teens not to do things like smoke, drink or do drugs, a Temple University psychologist suggests that competing systems within the brain make adolescents more susceptible to engaging in risky or dangerous behavior, and that educational interventions alone are unlikely to be effective.

15 Apr 2007

Gleevec decreases cancer recurrence for GIST

Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.

15 Apr 2007

Cytokinetics initiates of phase II clinical trial for CK-1827452

Cytokinetics has announced the initiation of a Phase II clinical trials program evaluating CK-1827452, a novel cardiac myosin activator for the potential treatment of patients with either acutely decompensated or chronic heart failure.

15 Apr 2007

Shutting down microglia

Developing brain tumors can coax assistance from nearby cells known as microglia, according to a new study from scientists at Washington University School of Medicine in St. Louis. The researchers have identified one protein made by microglia that helps accelerate tumor growth and are looking for others.

15 Apr 2007